shutterstock_1283238958_editorialcreditmariaxshutterstock-com
mariax / Shutterstock.com
14 May 2019Americas

Google fund invests in CRISPR start-up

Alphabet-owned GV (formerly Google Ventures) has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
17 April 2019   The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.

More on this story

Americas
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
17 April 2019   The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.

More on this story

Americas
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
17 April 2019   The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.